AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01372280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reminyl
Description: Galantamine Hydrobromide Tablets 4 mg
Study NCT03905746 — intervention group
Intervention type: OTHER
Intervention: blood sample at Day 0
Description: 40mL blood (plasma and PBMCs) will be performed at D0 (inclusion), at the time of routine exams.~(20 ml will be used for study analyzes ; 20mL will constitute the biological collection)
Study NCT03905746 — intervention group
Intervention type: OTHER
Intervention: blood sample at Day 2 and Day 7
Description: 20mL blood (plasma and PBMCs) will be performed at Day 2 and Day 7 from recruitment, at the time of routine exams. These two samples will constitute the biological collection.
Study NCT03905746 — intervention group
Intervention type: OTHER
Intervention: stool sample at Day 0
Description: stool sample (2mL) will be performed at D0 (inclusion), at the time of routine exams.
Study NCT01928524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS2w Dose level 1A
Description: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Study NCT01928524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS2w Dose level 2A
Description: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Study NCT01928524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS2w Dose level 3A
Description: Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Study NCT01928524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS2w Dose level 4A
Description: Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Study NCT01928524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS3w Dose level 1B
Description: Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Study NCT01928524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS3w Dose level 2B
Description: Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Study NCT01928524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS3w Dose level 3B
Description: Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Study NCT03285620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-034
Description: Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2
Study NCT03285620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
Study NCT00170716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortical Stimulation and rehabilitation
Description: Cortical stimulation is provided concomitantly with rehabilitation therapy. Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
Study NCT00170716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
Study NCT01252940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TDF
Description: Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
Study NCT01252940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI
Description: Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
Study NCT01252940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Ritonavir (RTV) was administered according to prescribing information.
Study NCT01252940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs
Description: NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
Study NCT02549183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific PRECISION Spinal Cord Stimulator System
Description: Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
Study NCT04487639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics
Description: a nasopharyngeal swab for SARS-CoV-2 research by RT- qPCR will be performed on the day of semen collection. On the same day, serological tests will be carried out, and 30 to 50 days after, according to HAS specifications with methods validated by the National Reference Center
Study NCT04277156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L rhamnosus ATCC 53103
Description: 5 drops contain Lactobacillus rhamnosus 5x10\^9 CFU.
Study NCT02932033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tack fixation of mesh
Description: hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) or spiral titanium tacks (active comparator) according to the result of randomization
Study NCT02932033 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Synthetic glue fixation
Description: hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) according to the result of randomization
Study NCT04386421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video on oral hygeine instructions
Description: A 3 minute video will be shown providing information regarding the care of the dentition during Fixed appliance treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions.
Study NCT04386421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plaque disclosing tablets
Description: Plaque disclosing tablets:~Product: 2-Tone Disclosing Tablets Young Dental Manufacturing 13705 Shoreline Court East Earth City, MO 63045 Composition: Flavor, SD Tutti Fruiti 1 %, D and C Red 1 % and FD and C Blue 1 %
Study NCT00634166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamylon® For 5 % Topical Solution
Description: Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
Study NCT00634166 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topical Antimicrobial/Antifungal Medications
Description: 'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.
Study NCT02581449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3
Description: dietary supplement
Study NCT02581449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: empty soft gelatin capsules
Description: empty softgels of matched size, shape and color
Study NCT00955591 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Papanicolaou test
Study NCT00081263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00081263 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00081263 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT01002703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Bendamustine, Prednisone
Description: During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
Study NCT01819558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recwt1-A10+AS01B
Study NCT03651518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kineret
Description: 100 mg, once/day sc 6 months
Study NCT03651518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira
Description: 40 mg/15 days sc 6 months
Study NCT03651518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stelara
Description: 45 mg/12 weeks sc, 6 months
Study NCT03651518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosentyx
Description: 300mg sc every week for 1 month, then 300 mg/month sc for 5 months
Study NCT03651518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roactemra
Description: 480 mg/perf/4 weeks 6 months
Study NCT03651518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 2 sessions of 1000 mg at inclusion and 15 days after inclusion
Study NCT02003066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard fluid therapy
Description: In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
Study NCT02003066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative fluid therapy
Description: In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
Study NCT03741946 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Triangle of Sedillot identification using ultrasonography
Description: Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
Study NCT03866538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of Oral Budesonide
Description: The intervention arm will taper and stop budesonide therapy (withdrawal).
Study NCT02110472 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Corneal inlay
Description: Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
Study NCT01531933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS3233
Description: For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
Study NCT01157949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: Study patients will receive 1.5 mg/kg/day intravenously for 5 days.
Study NCT01157949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thymoglobulin
Description: Study patients will receive 1.5 mg/kg/day intravenously for 5 days.
Study NCT02012998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBVAXPRO 5µg
Description: 0.5mL intramuscular injection
Study NCT03114813 — intervention group
Intervention type: DRUG
Intervention: Carvedilol
Description: Non-selective beta-blocker as per routine clinical care
Study NCT03114813 — intervention group
Intervention type: OTHER
Intervention: MRI scan
Description: One hour non-invasive MRI scan
Study NCT03114813 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatic Venous Pressure Gradient (HVPG)
Description: Second HVPG to evaluate treatment response
Study NCT05601258 — intervention group
Intervention type: OTHER
Intervention: Age, gender, hospitalization and mortality rates will be compared
Description: Age, gender, hospitalization and mortality rates will be compared
Study NCT02107027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nMARQ catheter
Description: In this arm the circular ablation catheter will be used for a quick mapping of left atrium with Carto system. The catheter will be positioned to pulmonary veins ostium to deliver radiofrequency on 1 to 10 electrodes simultaneous. The same catheter will be used to document pulmonary veins isolation (PVI).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) site(s) will be noted.
Study NCT02107027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navistar catheter
Description: In this arm the conventional catheter will be used. It will be used for a left atrium quick mapping on Carto system. Radiofrequency will be delivered in a sequential manner in pulmonary veins for point by point ablation. Isolation will be guided and confirmed with the Lasso decapolar diagnostic catheter (Biosense Webster, Diamond Bar, USA).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) sites will be noted.
Study NCT02315781 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
Study NCT02315781 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
Study NCT03269942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Flow-Diversion
Description: Implantation of flow-diverter in treatment of complex aneurysms of anterior circulation.
Study NCT03269942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral Revascularization
Description: Cerebral revascularization with trapping of aneurysm in treatment of complex aneurysms of anterior circulation.
Study NCT01531933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DLBS3233
Description: For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
Study NCT03755362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Dental evaluation at baseline, 3, 6, and 9 months.
Study NCT03755362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive Treatment
Description: Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to \<20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
Study NCT00877890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2.0mg, once a week
Study NCT00877890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide twice daily
Description: subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
Study NCT00652522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD/CRT implant
Description: Implantation of a ICD/ CRT device if not yet implanted
Study NCT00652522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICD/CRT implant
Description: Implantation of a ICD/ CRT device if not yet implanted
Study NCT00652522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation
Description: Atrial Fibrillation ablation by pulmonary vein isolation
Study NCT01669356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenteral supplement with enteral nutrition for patients after esophagectomy
Study NCT01669356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Nutrition alone for patients after esophagectomy
Study NCT00042770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: talc
Description: Given intrapleurally
Study NCT00042770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dyspnea management
Description: No talc
Study NCT03566927 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FLEX Scoring Catheter with Lutonix DCB
Description: Treatment by the FLEX Scoring Catheter, a plain balloon angioplasty, followed by a Lutonix DCB.
Study NCT00652522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
Study NCT00717561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
Study NCT01797003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High tibial osteotomy
Study NCT01554423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Testing and Counseling
Description: Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.
Study NCT01554423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview (BMI)
Description: The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
Study NCT00845260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (CBT).
Description: Self-help program and guidance by psychologist via e-mail during 10 weeks.
Study NCT00845260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT
Description: Group cognitive behavior therapy (CBT) during 10 weeks.
Study NCT01554423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Family and Cognitive Behavioral Therapy
Description: The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
Study NCT01743131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
Study NCT01743131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01940679 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated 600 mg EPA/DHA
Description: encapsulated 600 mg EPA/DHA